

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
4 September 2003 (04.09.2003)

PCT

(10) International Publication Number  
WO 03/072599 A2(51) International Patent Classification<sup>7</sup>:

C07K 7/00

(21) International Application Number:

PCT/IL03/00155

(22) International Filing Date:

27 February 2003 (27.02.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/359,995 28 February 2002 (28.02.2002) US

(71) Applicant (for all designated States except US):  
**BIOKINE THERAPEUTICS LTD.** [IL/IL]; Building 13a, Kiryat Weizmann, 70400 Nes Ziona (IL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **PELED, Amnon** [IL/IL]; Balfour Street 33b, 65211 Tel Aviv (IL). **EIZENBERG, Orly** [IL/IL]; Gordon Street 43A, 76287 Rehovot (IL). **VAIZEL-OHAVON, Dalit** [IL/IL]; HaOfek Street 2, 47027 Nes Ziona (IL).(74) Agent: **G.E. EHRLICH (1995) LTD.**; Bezalel Street 28, 52521 Ramat Gan (IL).


(81) Designated States (national): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



A2

WO 03/072599

(54) Title: NOVEL CHEMOKINE BINDING PEPTIDES CAPABLE OF MODULATING THE BIOLOGICAL ACTIVITY OF CHEMOKINES

(57) Abstract: Novel peptidic or peptidomimetic agents or small molecules for modulating the biological effect of a chemokine. According to the present invention, the therapeutic agents preferably are endowed with the capacity to bind to certain chemokines in order to modulate the biological interaction between the target ligand, chemokine, and the respective target receptor, chemokine receptor. These peptides may be described as agonist ligands or antagonists. Next, preferably certain peptides share consensus sequences which characterize the families or categories of these modulator peptides.

NOVEL CHEMOKINE BINDING PEPTIDES CAPABLE OF MODULATING  
THE BIOLOGICAL ACTIVITY OF CHEMOKINES

5 FIELD OF THE INVENTION

The present invention discloses novel peptidic molecules and every small molecule, which are capable of binding chemokines and modulating their biological functions.

10 BACKGROUND OF THE INVENTION

Drug discovery in the post-genomics era provides enormous opportunities as well as new challenges. The targets of the drug discovery process have changed greatly over the last 50 years. The development of advanced purification technologies and the tools of molecular biology have brought molecular targets into the current 15 discovery process. In the last ten years, there has been a trend towards selecting molecular targets for the screening process, and the human and other genome projects have made available many thousands of additional targets for drug discovery.

In addition to these novel targets with unknown potential, there are a significant number of well-validated targets associated with major human diseases. 20 Most of these are either nuclear receptors or G protein-coupled receptors. It was found, that in some cases, one compound which has an effect through one receptor, can also act through another receptor, and that several compounds can work through the same receptor. Unfortunately, even when the mechanism of a disease process is understood, for example by identifying the receptor(s) responsible for such a process, 25 this information has not always resulted in the development of new treatments. For

example, subjects who suffer from inflammation associated diseases and disorders have a great and desperate demand for novel drugs as therapeutic agents. Current therapies are merely palliative and have not been significantly improved in recent years.

5       Recent scientific advances provide some hope that new treatments will soon be available for these diseases. Sequencing of the human genome, which contains nearly 30,000 genes, has been recently completed. This significant achievement in the frontiers of human medicine will allow the identification of genes involved in the onset and progression of human diseases and pathological states. Many of these genes  
10      will serve as valid targets in the discovery process of drugs which will be more effective in the treatment of inflammatory diseases. Along with a massive flow of novel genes with potential therapeutic properties, there is a growing need for more rapid and efficient ways to discover lead compounds with enhanced (agonistic) or inhibitory (antagonistic) properties.

15       Chemokines are among the biological factors which are, amongst other functions, involved in the inflammatory disease process. Chemokines belong to a group of small, ~8-14 kDa, mostly basic, heparin binding proteins that are related both in their primary structure and the presence of 4 conserved cysteine residues. The chemokines are chemotactic cytokines that have been shown to be selective  
20      chemoattractants for leukocyte sub-populations *in vitro*, and to elicit the accumulation of inflammatory cells *in vivo*. In addition to chemotaxis, chemokines mediate leukocyte de-granulation (Baggiolini and Dahinden, 1994) and the up-regulation of adhesion receptors (Vaddi and Newton, 1994), and have recently been implicated in the suppression of human immunodeficiency virus replication (Cocchi et al., 1995).

Chemokines can be divided into 4 groups (CXC, CX3C, CC, and C) according to the positioning of the first 2 closely paired and highly conserved cysteines of the amino acid sequence. The specific effects of chemokines on their target cells are mediated by members of a family of 7-transmembrane-spanning G-protein-coupled receptors. These chemokine receptors are part of a much bigger super family of G-protein-coupled receptors that include receptors for hormones, neurotransmitters, paracrine substances, inflammatory mediators, certain proteinases, taste and odorant molecules and even photons and calcium ions.

The chemokine receptors have received increasing attention due to their critical role in the progression of immune disease states such as asthma, atherosclerosis, graft rejection, AIDS, multiple sclerosis and others. It would be useful to have therapeutic agents capable of inhibiting the binding of ligands of some chemokine receptors in order to lessen the intensity of or cure these diseases. Chemokines themselves play an essential role in the recruitment and activation of cells from the immune system. They also have a wide range of effects in many different cell types beyond the immune system, including for example, in various cells of the central nervous system (Ma et al., 1998) or endothelial cells, where they result in either angiogenic or angiostatic effects (Strieter et al., 1995). Recent work has shown that particular chemokines may have multiple effects on tumors, including promoting growth, angiogenesis, metastasis, and suppression of the immune response to cancer, while other chemokines inhibit tumor mediated angiogenesis and promote anti-tumor immune responses. Recently, it was shown that the SDF-1 $\alpha$ /CXCR4 chemokine/chemokine receptor pathway is involved in dissemination of metastatic breast carcinomas (Muller A, 2001). This example illustrates that both chemokines

and their receptors are potentially valuable targets for therapeutic intervention in a wide range of diseases.

5 **SUMMARY OF THE INVENTION**

The background art does not teach or suggest sequences or compositions containing peptidic modulators capable of binding to chemokines and inhibiting or activating their biological functions. The background art also does not teach or suggest sequences or compositions containing the basic consensus sequences which 10 characterize families of such peptidic chemokine-binding modulators. In addition, the background art does not teach or suggest the nucleic acid molecules encoding for such peptidic chemokine-binding modulators. Finally, the background art does not teach or suggest methods of treatment employing such peptidic chemokine-binding modulators.

15 The present invention overcomes these deficiencies of the background art by providing peptidic chemokine-binding modulators, with defined amino acid sequences, which have been found to bind to specific chemokines, including but not limited to human SDF-1 $\alpha$ , MIG, IL-8, MCP-1 and Eotaxin, and which modulate the binding of these chemokines to their respective receptors and/or which otherwise have 20 an inhibitory or stimulatory effect on the biological activity of chemokines.

It should be noted that the term "peptidic" as used herein, also includes peptidomimetics and hybrid structures comprised of at least one amino acid and at least one molecule that is not an amino acid, or at least not a naturally occurring amino acid. The term amino acid may optionally also include non-naturally occurring 25 amino acids as well as naturally occurring amino acids, and derivatives and analogs

thereof. It also includes every small molecule, regardless of whether that molecule is a peptide, that binds to one or more of the chemokines.

Preferably, the present invention features basic consensus sequences which characterize families of such peptidic chemokine-binding modulators.

5 More specifically, if the biological activity caused by the target protein, i.e. chemokine receptor, when activated through binding the target ligand, i.e. chemokine, involves activation of some biological function, then the inhibitory peptide preferably inhibits such activation. On the other hand, if the biological activity caused by the receptor involves inhibition of some biological function, then the inhibitory peptide 10 preferably blocks inhibition of the biological function.

The peptidic chemokine-binding modulators are then preferably used to develop one or more lead compounds for new therapies. Alternatively or additionally, the peptidic chemokine-binding modulators themselves may have therapeutic value, and as such, may optionally be used for treatment of a subject.

15 Also additionally or alternatively, binding of the peptidic chemokine-binding modulators may optionally be used to identify lead proteins, which are reference proteins whose reactivity descriptors are substantially similar to those of the protein of interest such as novel chemokines.

Also additionally or alternatively, the peptidic chemokine-binding modulators 20 may optionally be used as antigens to produce antibodies to these peptides, which can also bind chemokine-binding receptors, or optionally may be used to stimulate the production of auto-antibodies against these peptides that can also bind chemokine receptors. The latter use would involve using these peptides (or other modulators) as a vaccine, optionally with any suitable vaccine carrier that could easily be selected by 25 one of ordinary skill in the art, including but not limited to, adjuvants, carriers and the

like. More preferably, the modulators which are used to produce the antibodies are selected from one of the peptides described herein. It should be noted that the vaccine may also optionally comprise the antibody itself.

According to another preferred embodiment of the present invention, there is provided a composition for treating inflammatory and cancer metastasis conditions in a subject, comprising a pharmaceutically effective amount of a therapeutic agent for administering to the subject, the therapeutic agent being composed of the peptidic chemokine-binding modulators as the active ingredient as well as a suitable pharmaceutical carrier if necessary.

According to a preferred embodiment of the present invention, the therapeutic agent may be administered topically, intranasally and by inhalation. Alternately, the therapeutic agent may be administered by systemic administration.

According to the present invention, there is provided a peptidic chemokine modulator for modulating a biological effect of a chemokine, comprising a molecule composed of the amino acids H, S, A, L, I, K, R, T and P, and featuring at least 2 Histidines spread along the molecule, wherein the molecule features an overall positive charge (family 1). Preferably, the molecule comprises a peptide having an amino acid sequence selected from the group consisting of SIFAHQTPTHKN, SIPSWSIHSAKA, SAISDHRAHRSH, SAGHIHEAHRPL, CHASLKRC, AHSLKSITNHGL, ESDLTHALHWLG, HSACHASLKRC, WSAHIVPYSHKP, YATQHNWRLKHE, CAHLSPHKC, GVHKHFYSRWLG, HPTTPIHMPNF, SVQTRPLFHSHF, and VHTSLLQKHPLP. More preferably, the peptide has an amino acid sequence SIFAHQTPTHKN. The peptidic chemokine modulator may optionally be used for binding to a chemokine selected from the group comprising MIG, MCP-1, IL-8, SDF-1 alpha and Eotaxin.

According to another embodiment of the present invention, there is provided a peptidic chemokine modulator for modulating a biological effect of a chemokine, comprising a molecule composed of the amino acids H, P, T, L, R, W, F, and featuring at least two neighboring histidines, wherein the molecule features an overall

5 positive charge (family 2). Preferably, the molecule comprises a peptide having an amino acid sequence selected from the group consisting of GDFNSGHHTTR, HHFHLPKLRPPV, HHTWDTRIWQAF, LDYPIPQTVLHH, LLADTTTHHRPWP, TRLVPSRYYHHP, CHHNLNSWEC and SFWHHHSPRSPL. More preferably, the peptide has an amino acid sequence LLADTTTHHRPWP.

10 According to another embodiment of the present invention, there is provided a composition for treating a condition involving abnormal cell migration in a subject, the composition comprising a pharmaceutically effective amount of a therapeutic agent for administering to the subject, the therapeutic agent comprising a chemokine modulator as described above. Preferably, the condition comprises an inflammatory  
15 condition. Alternatively, the condition comprises cancer metastasis. Optionally, the therapeutic agent is administered by topical administration, such that the composition further comprises a pharmaceutically acceptable carrier for topical administration. Preferably, the topical administration is to the skin of the subject. Optionally, the therapeutic agent is administered by inhalation, such that the composition further  
20 comprises a pharmaceutically acceptable carrier for inhalation. Alternatively, the therapeutic agent is administered intranasally, such that the composition further comprises a pharmaceutically acceptable carrier for intranasal administration.

Optionally, the therapeutic agent is characterized by an ability to inhibit binding of the chemokine to a chemokine receptor.

Optionally, the therapeutic agent is characterized by an ability to enhance binding of the chemokine to a chemokine receptor.

According to another embodiment of the present invention, there is provided a method for treating a disease modulated through and/or caused by binding of a 5 chemokine to a chemokine receptor in a subject, comprising administering a pharmaceutically effective amount of a therapeutic agent to the subject, the therapeutic agent comprising a peptidic chemokine modulator as described above.

Preferably, the therapeutic agent binds to at least one of the chemokines and wherein the therapeutic agent directly modulates the activity of the chemokine by 10 modulation of binding to the chemokine receptor.

Optionally and preferably, the disease is selected from the group consisting of: inflammation (primary or secondary), allergy, a non-optimal immune response, an autoimmune reaction (including rheumatoid arthritis, systemic lupus erythematosis, multiple sclerosis and others), allograft rejection, diabetes, sepsis, cancer and any type 15 of malignant cell growth, acute and chronic bacterial and viral infections, arthritis, colitis, psoriasis, atherosclerosis, hypertension and reperfusion ischemia.

According to still another embodiment of the present invention, there is provided an antibody for binding to a chemokine-binding receptor, comprising: an antibody being capable of recognizing at least a portion of a chemokine-binding 20 receptor, wherein the antibody also recognizes a peptide having a sequence as described above.

Optionally, there is also provided a vaccine formed with the above antibody.

According to still another embodiment of the present invention, there is provided a method for producing an antibody, comprising: inducing formation of 25 antibody against a peptide having a sequence according to the above description,

wherein the antibody is also capable of recognizing a chemokine-binding receptor.

Preferably, the antibody comprises a monoclonal antibody. Alternatively, the antibody comprises a polyclonal antibody. Preferably, the antibody forms a vaccine.

Hereinafter, the term "biologically active" refers to molecules, or complexes 5 thereof, which are capable of exerting an effect in a biological system. Hereinafter, the term "fragment" refers to a portion of a molecule or a complex thereof, in which the portion includes substantially less than the entirety of the molecule or the complex thereof.

Hereinafter, the term "amino acid" refers to both natural and synthetic 10 molecules which are capable of forming a peptide bond with another such molecule.

Hereinafter, the term "natural amino acid" refers to all naturally occurring amino acids, including both regular and non-regular natural amino acids. Hereinafter, the term "regular natural amino acid" refers to those alpha amino acids which are normally used as components of a protein. Hereinafter, the term "non-regular natural 15 amino acid" refers to naturally occurring amino acids, produced by mammalian or non-mammalian eukaryotes, or by prokaryotes, which are not usually used as a component of a protein by eukaryotes or prokaryotes. Hereinafter, the term "synthetic amino acid" refers to all molecules which are artificially produced and which do not occur naturally in eukaryotes or prokaryotes, but which fulfill the required 20 characteristics of an amino acid as defined above. Hereinafter, the term "peptide" includes both a chain and a sequence of amino acids, whether natural, synthetic or recombinant. Hereinafter, the term "peptidomimetic" includes both peptide analogues and mimetics having substantially similar or identical functionality thereof, including analogues having synthetic and natural amino acids, wherein the peptide bonds may 25 be replaced by other covalent linkages.

BRIEF DESCRIPTION OF THE DRAWINGS AND TABLES

The invention is herein described, by way of example only, with reference to the accompanying drawings and tables, wherein:

5 FIG. 1 shows the results of binding of chemokines to BKT-P1, BKT-P3, BKT-P22, and BKT-P37 peptides, which bind, respectively, to at least one of the following chemokines, SDF-1 $\alpha$ , MCP-1, Eotaxin and IL-8;

10 FIG. 2 shows the binding of synthetic peptides from Table 1 which can either bind to various chemokines (such as BKT-P1, shown in Fig. 2B), or can alternatively bind specifically to a single chemokine (such as BKT-P9 alone, as shown in Fig 2A);

FIG. 3 shows the results of binding of one of the synthetic peptides from family 1, BKT P3, to various chemokines. BKT-P18, which does not belong to the family, is shown as a control;

15 FIG. 4 shows a graphical representation of the biological activity results for BKT-P3, from family 1 in a biovalidation assay system in which the chemokine MIG and the adhesion receptor VCAM-1 are used to activate the binding of T cells (see “Material and Methods”) (FIG. 4A); BKT-P10, which does not belong to the family, is shown as a control (FIG. 4B).

20 Fig. 5 shows a graphical representation, of the level of immunity (O.D.) of antibody raised against BKT-P3 and BKT-P2, belongs to family 1, to the relevant peptides, BKT-P3 and BKT-P2. The preimmune serum of the same mice used as a control. “Blank” is the O.D. level of antibody binding to the plastic (of the Elisa experiment), with no addition of peptides.

25 Table 1 shows the sequences of peptides that bind to the chemokines MCP-1, SDF-1 $\alpha$ , MIG, Eotaxin and IL-8;

Table 2 shows a family of peptides (family no. 1) that bind to MIG, MCP-1, IL-8, SDF-1 $\alpha$  and Eotaxin and are predominantly composed of the amino acids H, S, A, L, I, K, R, T and P, featuring at least 2 Histidines spread along the molecule. The abundance of positively charged amino acids such as H, K and R, resulted in peptides 5 having an overall positive charge. The remaining amino acids, mentioned above, might participate in the determination of the three dimensional structure of the peptides;

Table 3 shows a family of peptides (family no. 2) that bind mostly to MCP-1 and in individual cases to IL-8, SDF-1- $\alpha$  and Eotaxin; the binding motif for peptides in this family is predominantly composed of the amino acids H, P, T, L, R, W, F, 10 featuring at least 2 Histidines next to each other. The abundance of positively charged amino acids, such as H and R, resulted in peptides having an overall positive charge. The remaining amino acids, mentioned above, might participate in the determination of the three dimensional structure of the peptides;

Table 4 shows a summary of the results of the biological activity of four 15 representatives from family 1, in a biovalidation assay system, in which various chemokines and the adhesion receptor VCAM-1 are used to activate the binding of T cells (as described in "Materials and Methods").

#### DESCRIPTION OF THE PREFERRED EMBODIMENTS

20 The present invention is composed of peptidic modulatory molecules with defined amino acid sequences which have been found to bind to specific chemokines, including, but not limited to, human SDF-1 $\alpha$ , MIG, IL-8, MCP-1 and Eotaxin, and which inhibit or stimulate the binding of these chemokines to their respective receptor/s and/or which otherwise have an inhibitory or stimulatory effect on the 25 biological activity of chemokines. Preferably, the present invention specifies basic

consensus sequences, with overall positive electrostatic charge, which characterize families of such modulatory chemokine-binding peptide molecules.

The chemokine binding peptides mimic chemokine receptor structures or motifs. It is therefore predicted that the chemokine-binding peptides, when injected or otherwise introduced into mice or humans, may produce antibodies against chemokine receptors that can be either used for the production of monoclonal antibodies or used for development of a vaccine against a particular chemokine receptor. Whether antibodies are produced, or alternatively, binding to a particular chemokine receptor is blocked and/or enhanced, may depend upon the method of introduction to the subject. For example, antibody production may be potentiated if the peptides (and/or other peptidic modulatory molecule according to the present invention) are introduced with an adjuvant. Concentration of the peptide or other molecule may also be important. In any case, one of ordinary skill in the art could easily determine conditions for antibody production, as opposed to having the effect potentiated or mediated directly through the peptides and/or other peptidic modulatory molecules according to the present invention.

The modulatory chemokine-binding peptide molecules of the present invention could therefore be useful for treating a disease selected from the group consisting of inflammation (primary or secondary e.g. uveitis, bowel inflammation), allergy, non-optimal immune response, autoimmune reaction (including rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and others), delayed-type hypersensitivity, allograft rejection, diabetes, sepsis, cancer and any type of malignant cell growth, (including, but not limited to breast cancers such as infiltrating duct carcinoma of the breast or other metastatic breast cancers, lung cancers such as small cell lung carcinoma, bone cancers, bladder cancers such as bladder carcinoma,

5 rhabdomyosarcoma, angiosarcoma, adenocarcinoma of the colon, prostate or pancreas, or other metastatic prostate or colon cancers, squamous cell carcinoma of the cervix, ovarian cancer, malignant fibrous histiocytoma, skin cancers such as malignant melanoma, lymphomas and leukemia, leiomyosarcoma, astrocytoma, glioma and hepatocellular carcinoma), acute and chronic bacterial and viral infections, vasculitis, arthritis, colitis, psoriasis, atherosclerosis, Graves disease, anorexia nervosa; hemorrhagic shock caused by septicemia, HIV infection in AIDS, pemphigus, asthma, renal diseases, liver diseases, bone marrow failure, vitiligo, alopecia, and myositis, hypertension and reperfusion ischemia.

10 The examples provided below, describe certain experiments performed with the peptidic modulatory of the present invention, demonstrating the binding efficacy of these molecules to the various chemokines. It also demonstrates the efficacy of the peptidic chemokine-binding modulator in a biological system. In addition, the examples also describe formulations for administering the compounds of the present  
15 invention, and methods of treatment thereof.

#### EXAMPLE 1

##### EFFICACY OF THE PEPTIDES OF THE PRESENT INVENTION

This Example demonstrates the efficacy of the peptidic chemokine-binding  
20 modulators of the present invention, in a number of different assays, including binding assays and assays for measuring a functional biological effect.

#### **Materials and methods**

##### **Chemokines**

Recombinant chemokines were ordered from PeproTech, Inc. (Rocky Hill, NJ, USA). Human SDF-1 $\alpha$  (Cat. No. 300-28A), human MIG (Cat. No. 300-26) and human IL-8, (72 amino acids) (Cat. No. 200-08M), belong to the  $\alpha$ -chemokines (C-X-C) family. Human MCP-1 (MCAF) (Cat. No. 300-04) and human Eotaxin (Cat. No. 300-21) belong to the beta-chemokines (C-C family). All chemokines were prepared according to the company recommendations.

#### Peptide synthesis

Peptides were synthesized in the Weizmann Institute of Science, Rehovot, Israel, in order to perform tests for characterization of their influence on the biological activity of the chemokines. The format of the various synthesized peptides was as follows: The cyclic peptides, ACX<sub>7</sub>CGGGSK-biotin-G and the linear peptides, X<sub>12</sub>GGGSK-biotin-G. The peptides were biotinylated on their C-termini; the biotin will serve as a detector during the following experiments. Each synthetic peptide was dissolved to concentration of 1mg/ml (~0.6 mM) in 4% DMSO (Dimethyl Sulphoxide, Sigma, Cat. # D-2650).

#### ELISA analysis of the synthetic chemokine-binding peptide

NUNC-Immuno maxisorp plates (Cat. No. 4-42404) were coated with the appropriate chemokine (0.1 ml/well, 0.1-1.0  $\mu$ g/ml in 0.1 M NaHCO<sub>3</sub>, pH 8.6), overnight at 4°C. The plates were then blocked with 0.2 ml/well of blocking buffer (5mg/ml BSA in 0.1 NaHCO<sub>3</sub>). Control wells were treated with blocking buffer alone, with no addition of target protein (chemokine). The plates were washed 6 times with PBST (0.1% Tween 20 in PBS), followed by incubation for 45 minutes at room temperature with 10-fold serial dilutions of individual synthetic peptides (10pg-10 $\mu$ g).

with 1%BSA (PBST-BSA)/well. After the plates were washed 6 times with PBST, the bound peptides were probed by HRP-SA Conjugate, diluted 1:10,000 to 1:20,000 in PBST-BSA, 0.1 ml/well for 45 minutes at room temperature. The target-bound synthetic peptides probed with HRP-SA were quantified by DAKO TMB one-step substrate system, followed by the addition of stop solution, HCl-H<sub>2</sub>SO<sub>4</sub> mixture (0.1 ml/well) (1N HCl, 3N H<sub>2</sub>SO<sub>4</sub>). The results were analyzed by ELISA reader at OD<sub>450</sub>.

#### Biovalidation

Laminar flow assays were performed as follows. Polystyrene plates (B.D) 10 were coated with soluble VCAM-1 at 10 µg/ml in the presence of 2 µg/ml HSA carrier. The plates were washed three times with PBS and blocked with HSA (20 µg/ml in PBS) for 2 hrs at room temperature. Alternatively, washed plates were coated with 10 µg/ml MIG chemokine in PBS for 30 min at room temperature, before being blocked with HSA. The plates were assembled as the lower wall of a parallel 15 wall flow chamber and mounted on the stage of an inverted microscope. The peptide, as described previously, (10µg/ml) was allowed to settle on the substrate coated chamber wall for 10 min, at 37°C and then washed. T cells (5x10<sup>6</sup>/ml, purity >98%) were suspended in binding buffer, perfused into the chamber and allowed to settle on the substrate coated chamber wall for 1 min, at 37°C. Flow was initiated and 20 increased in 2 to 2.5 fold increments every 5 sec. generating controlled shear stresses on the wall. Cells were visualized in a 20x objective of an inverted phase-contrast Diaphot Microscope (Nikon, Japan) and photographed with a long integration LIS-700 CCD video camera (Applitech; Holon, Israel), connected to a video recorder (AG-6730 S-VHS, Panasonic, Japan). The number of adherent cells resisting 25 detachment by the elevated shear forces was determined after each interval by

analysis of videotaped cell images, and was expressed as the percent of originally settled cells. All adhesion experiments were performed at least three times on multiple test fields.

## 5 Results

### **Identification of chemokine binding peptides with antagonistic effect**

The present invention identifies chemokine-binding peptides with biological activity. The binding specificities of the various peptides to the chemokines were determined by screening against BSA, Actin and Fibronectin-coated wells as negative 10 controls in parallel experiments. The binding level of the peptides to the various chemokines, which reached at least two fold of the binding level to the control proteins, was considered a specific binding. The different peptides that were found to bind to chemokines, are listed in Table 1.

Graphical representations of four examples of such peptide-containing carriers, 15 from the list in Table 1, are shown in Figure 1. As can be seen, each of those peptides was found to bind to at least one different chemokine, which was chosen to be presented in this graph: peptide BKT-P1 was found to bind SDF-1 $\alpha$ ; peptide BKT-P3 was found to bind, in this representation, to MCP-1; peptide BKT-P22, was found to bind Eotaxin and peptide BKT-P37, was found to bind IL-8. The specificity of the 20 binding was calculated by comparing the binding level of the proteins to chemokines to that of binding level to control proteins, as explained above. It should also be noted that the binding of each of the peptides shown in Figure 1 is not necessarily the only binding capability shown by those peptides.

Peptides that showed affinity/binding to one or more chemokines were then 25 analyzed in several individual experiments, and were chosen for further analysis. The

specific binding of the peptides was detected by screening methodology, using ELISA, as described in "Materials and Methods", employing microplates coated with the various chemokines to be checked. The binding specificities of the various peptides to the various chemokines were determined by screening against BSA, Actin 5 and Fibronectin-coated wells as negative controls in parallel experiments.

As can be seen in Figure 2, peptides which can specifically bind to one specific chemokine, such as BKT-P9, were identified (Fig. 2A). In addition, peptides which can bind to more than one chemokine, such as BKT-P1, were also identified (Fig. 2B). Again, the specificity of the binding, either to one chemokine or more, was 10 established by comparing binding level with the control binding level to non-related proteins, (shown in the Figure as a broken line). Control binding showed a level of one fold increase. As such, each of the peptides which showed a level of binding to a particular chemokine of less than, or close to, such a one-fold increase, was considered to be non-specifically bound to that chemokine. Specific binding was 15 considered as that which showed at least a two fold increase over the control binding level. Peptides that specifically bound to one or more chemokines were chosen for further examination and for analysis with a biovalidation assay, to prove their ability to not only bind the various chemokines but also to modulate the biological activity of those chemokines.

According to the present invention, two families of chemokine-binding 20 peptides were identified. These families contain peptides with similar amino acid compositions, a high percentage of histidines, and are also characterized by overall positive electrostatic charge.

A detailed list of the potential consensus sequences of the two families is 25 presented in Tables 2 and 3. The peptides of family no. 1 (Table 2) bind to MIG,

MCP-1, IL-8, SDF-1 $\alpha$  and Eotaxin, as illustrated in Table 2, and are predominantly composed of the amino acids H, S, A, L, I, K, R, T and P. Each peptide in this family contains at least 2 histidines distributed along the molecule. The abundance of positively charged amino acids such as H, K and R, results in peptides having an 5 overall positive charge. The remaining amino acids, mentioned above, might participate in the determination of the three dimensional structure of the peptides.

Table 3 shows a family of peptides (family no. 2) that bind mostly to MCP-1 and in individual cases to IL-8, SDF-1 $\alpha$  and Eotaxin (illustrated in the Table). The binding motif for peptides in this family is predominantly composed of the amino acids 10 H, P, T, L, R, W, F, while each peptide also features at least two histidines, one next to the other. The abundance of positively charged amino acids such as H and R, resulted in peptides having an overall positive charge. The remaining amino acids, mentioned above, may participate in the determination of the three dimensional structure of the peptides.

15 As defined here, a consensus sequence is composed of an amino acid sequence that is found repeatedly in a group of peptides which bind various chemokines and probably have certain biological functions in common. The group or family of such peptides is characterized by the consensus sequence, high abundance of the amino acid histidine and overall positive electrostatic charge. These peptides may be 20 described as potential agonists or antagonists of chemokines.

The binding of one synthetic peptide, BKT-P3 (family 1), to various chemokines is shown in Figure 3. As can be seen, this peptide binds to all five chemokines tested, in contrast to the control peptide, BKT-P18, which does not belong to the family, and also shows no binding to the chemokines. As discussed 25 above, the level of binding was calculated by comparing binding of the peptides to the

chemokines with peptide binding to controls. Level of control binding was defined as level 1 (up to a one-fold increase in binding). This control binding level is illustrated in the Figure as a dashed line. It can be seen that although BKT-P3 binds several different chemokines, the level of the binding is different in each case, which suggests 5 different affinities and maybe different influences on the activity of each of the chemokines.

Further examination of BKT-P3 for efficacy in biovalidation was performed to check the ability of BKT-P3 to bind and modulate the activity of MIG chemokine, to which BKT-P3 showed the highest binding level (Fig. 3). The result of the experiment 10 is graphically illustrated in Figure 4.

As can be seen in Figure 4B, when a control peptide which does not belong to the family was added to the flow chamber in order to test for its ability to bind to and modulate the activity of MIG, no influence on the activity of MIG was seen. MIG activity continued to show the same level of activity (about 25% of arrested cells) as 15 was seen in the absence of peptide. Hence, as can be seen in FIG. 4B the same percentage of arrested cells could be detected in the presence of the chemokine, with or without the addition of BKT-P10 (the control peptide) (Fig 4B, Mig+p10 and Mig, respectively). On the other hand, when BKT-P3 was added to the flow chamber, the percentage of arrested cells that reached about 30% in the presence of Mig (Fig. 20 4A, Mig), was dramatically reduced (Fig. 4A, Mig + p3) to the control level achieved in the presence of VCAM-1 alone, with no addition of chemokine (Fig. 4A, control). These results revealed an obvious antagonistic effect of BKT-P3 against human MIG, the chemokine to which it was able to bind (Figure 4A), in contrast to the non-binding control peptide, BKT-P10 (Figure 4B).

Table 4 shows a summary of the biological activity results for four representative synthetic peptides belonging to family 1. Various different chemokines were used in the biovalidation assay together with the adhesion receptor VCAM-1, in order to activate the adhesion of T cells in the system (as described in "Materials and Methods") As can be seen in Table 4, all the peptides that were checked clearly showed antagonistic effect on the various chemokines that were introduced into the flow chamber. On the other hand, although all the peptides showed antagonistic effects, the efficiency of the effect varied between the different peptides and between the same peptides tested against different chemokines. Thus, BKT-P3 caused complete arrest of the biological activity of both chemokines that were checked, MIG and IL-8. BKT-P2, which shows high sequence similarity to BKT-P3, caused only about 50% reduction in the activity of MIG. BKT-P45, which caused 100% abolishment of the activity of IL-8, as did BKT-P3, only reduced the activity of MIG by about 20%. BKT-P39, on the other hand, which had no effect on IL-8, caused 100% blocking of the activity of Eotaxin. It therefore seems that although the sequence similarity between the members of the family is quite high, the amino acid composition (the percentage of each amino acid in the final peptide sequence) and their particular order within the peptide sequence are important.

Further examination of BKT-P3 and BKT-P2 (both belonging to family 1) for the immunity of these peptides, was performed by injecting those peptides to mice. The result of the experiment is graphically illustrated in Figure 5. The control, preimmune serum of the same mice to which the peptides were injected, showed no binding to the two peptides (the O.D. results of both preimmune sera were the same as the O.D. achieved by binding of all sera to the plastic with no peptide addition). On the other hand, the immune sera showed high O.D. levels, in the presence of the two

peptides. These results showed that the sera collected from the mice after injection of the peptides probably contain antibodies against the two peptides.

The results summarized above are very important, since it is known that one chemokine can bind to more than one receptor and as such, can be involved in more than one pathological disorder. On the other hand, more than one chemokine can bind to one receptor, which means that several chemokines might be involved in one pathological disorder. So, in some cases, in order to block one pathological disorder, one may need to block the activity induced by more than one chemokine. Alternatively, in some cases, the activity of only one specific chemokine may need to be blocked in order to interfere with the progression of one specific pathological disorder.

The results, shown in FIGS. 2 and 3, and Table 4, demonstrate that there is a possibility of modulating either the activity of one specific chemokine, or the activity of several different chemokines which lead to the development of one pathological disorder, and thereby interfering with the progression of the various diseases.

The results shown in Figure 5 demonstrate the immunogenicity of the peptides. The ability to raise antibodies against the peptides, which would therefore mimic the chemokine receptors, provides support to other applications of the present invention, including but not limited to, the development of vaccines against the chemokine receptors. These receptors are known to be involved in various pathological disorders. Such vaccines would thus enable treatment and/or prevention of such disorders.

METHODS AND COMPOSITIONS FOR ADMINISTRATION

The peptides of the present invention, and their homologues, derivatives or related compounds, hereinafter referred to as the "therapeutic agents of the present invention", can be administered to a subject by various ways, which are well known in the art. Hereinafter, the term "therapeutic agent" includes a peptidic chemokine-binding modulator, as previously defined, including but not limited to, any of the above biologically useful peptides and their homologs, analogs, peptidomimetics and derivatives thereof.

Hereinafter, the term "subject" refers to the human or lower animal to which the therapeutic agent is administered. For example, administration may be done topically (including ophthalmically, vaginally, rectally, intranasally and by inhalation), orally, or parenterally, for example by intravenous drip or intraperitoneal, subcutaneous, or intramuscular injection.

Formulations for topical administration may be included but are not limited to lotions, ointments, gels, creams, suppositories, drops, liquids, sprays and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.

Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, sachets, capsules or tablets. Thickeners, diluents, flavorings, dispersing aids, emulsifiers or binders may be desirable.

Formulations for parenteral administration may include but are not limited to sterile aqueous solutions, which may also contain buffers, diluents and other suitable additives.

Dosing is dependent on the severity of the symptoms and on the responsiveness of the subject to the therapeutic agent. Persons of ordinary skill in the art can easily determine optimum dosages, dosing methodologies and repetition rates.

5

### EXAMPLE 3

#### METHODS OF TREATMENT WITH THE COMPOUNDS

As noted above, the therapeutic agents of the present invention have been shown to be effective modulators of cell adhesion and cell migration which characterize inflammatory reaction, cancer metastasis and any other suitable 10 conditions in which a particular target ligand binds to its target receptor. The following example is an illustration only of a method of treating an inflammatory condition, cancer metastasis and any other suitable condition involving cell migration, with the therapeutic agent of the present invention, and is not intended to be limiting.

The method includes the step of administering a therapeutic agent, in a 15 pharmaceutically acceptable carrier, to a subject to be treated. The therapeutic agent is administered according to an effective dosing methodology, preferably until a predefined endpoint is reached, such as the absence of a symptom of the inflammatory condition, blockage of tumor metastasis and any other suitable condition in the subject, or the prevention of the appearance of such a condition or symptom in the 20 subject.

The modulatory chemokine-binding peptide molecules of the present invention could therefore be useful for treating a disease selected from the group consisting of 25 inflammation (primary or secondary e.g. uveitis, bowel inflammation), allergy, non-optimal immune response, autoimmune reaction (including rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and others), delayed-type

hypersensitivity, allograft rejection, diabetes, sepsis, cancer and any type of malignant cell growth, (including, but not limited to breast cancers such as infiltrating duct carcinoma of the breast or other metastatic breast cancers, lung cancers such as small cell lung carcinoma, bone cancers, bladder cancers such as bladder carcinoma, 5 rhabdomyosarcoma, angiosarcoma, adenocarcinoma of the colon, prostate or pancreas, or other metastatic prostate or colon cancers, squamous cell carcinoma of the cervix, ovarian cancer, malignant fibrous histiocytoma, skin cancers such as malignant melanoma, lymphomas and leukemia, leiomyosarcoma, astrocytoma, glioma and heptocellular carcinoma), acute and chronic bacterial and viral infections, 10 vasculitis, arthritis, colitis, psoriasis, atherosclerosis, Graves disease, anorexia nervosa; hemorrhagic shock caused by septicemia, HIV infection, pemphigus, asthma, renal diseases, liver diseases, bone marrow failure, vitiligo, alopecia, and myositis, hypertension and reperfusion ischemia.

Table 1.

Peptide Name	Sequence of peptide
BKT-P50	AHLSPHK
BKT-P10	DIPWRNE
BKT-P17	DPLRQHS
BKT-P58	DSLGHWL
BKT-P15	DYTTRHS
BKT-P59	HGTLNPE
BKT-P56	HHNLSWE
BKT-P60	HIWTLAS
BKT-P61	HNTFSPR
BKT-P62	IPLHASL
BKT-P63	ITTTSLS
BKT-P64	KLTTCKD
BKT-P65	KNHTTFW
BKT-P66	LKLLSRS
BKT-P67	LLKAHPS
BKT-P68	LNQLKQA
BKT-P69	MNFPSPH
BKT-70	PQSPTYT
BKT-P57	PSSAIHT
BKT-P71	PTSTARI
BKT-P72	QASSFPS
BKT-P73	QPYFWYR
BKT-P14	QTLTPSI
BKT-P74	SKLGHLW
BKT-P75	SKTPERI
BKT-P76	SNNNRMT
BKT-P77	SPILSLS
BKT-P16	SPTNFTR
BKT-P78	SRPAMNV
BKT-P79	STKAYPN

Peptide Name	Sequence of peptide
BKT-P80	STSSCGS
BKT-P81	SYWGHRD
BKT-P13	TAHDANA
BKT-P82	TANSEKT
BKT-P83	THPKASM
BKT-P84	TKTINGK
BKT-P85	TNMQSPL
BKT-P86	TPFTKLP
BKT-P87	TPTTDISI
BKT-P88	TQQNGHP
BKT-P11	TTPSKHQ
BKT-P12	ACTTPSKHQC
BKT-P89	TYNVAKP
BKT-P90	ACAPLMFSQC
BKT-P48	ACHASLKHRC
BKT-P91	AHFSPNLLGG
BKT-P44	AHSLKSITNHGL
BKT-P92	AKTLMPSPFPPRT
BKT-P93	ASAVGSLSIRWQ/L/G
BKT-P94	ASWVDSRQPSAA
BKT-P95	CPQLTVGQHRT
BKT-P8	DLPPTLHTTGSP
BKT-P96	DSSNPIFWRPSS
BKT-P97	EFLGVPASLVNP
BKT-P51	ESDLTHALHWLG
BKT-P98	EVHSTDYRSIP
BKT-P99	FGLQPTGDIARR
BKT-P9	FSMDDPERVRSP
BKT-P100	FSPLHTSTYRPS
BKT-P27	GDFNSGHHTTTR
BKT-P28	GPSNNLPWSNTP

Peptide Name	Sequence of peptide
BKT-P33	GVHKHFYSRWLG
BKT-P101	HAPLTRSPAPNL
BKT-P102	HGSLLTTLF/LRYEP
BKT-P45	HHFHLPKLRPPV
BKT-P55	HHTWDTRIWFQAF
BKT-P54	HPTTPFIHMPNF
BKT-P103	HRDPXS(P)PSAA/GRP
BKT-P104	HNVTTRTQRLMP
BKT-P49	HSACHASLKHRC
BKT-P105	HSACKLTTCKDG
BKT-P6	HSACLSTKTNIC CLSTKTNIC ACLSTKTNIC ACLSTKTNIC ACLSTKTNIC
BKT-P106	IAHVPETRLAQM
BKT-P107	IFSMGTALARPL
BKT-P108	INKHPQQVSTLL
BKT-P7	ISPSHSQAQADL
BKT-P46	LDYPIPQTVLHH
BKT-21	LFAAVPSTQFFR
BKT-P22/38	LGFDPTSTRFYT
BKT-P37	LLADTTHHRPWT
BKT-P109	LPWAPNLPDSTA
BKT-P110	LQPSQPQRFAPT
BKT-P111	LSPPMQLQPTYS
BKT-P112	MHNVSDSNDSAI
BKT-P113	NSSMLGMLPSSF
BKT-P114	NTSSSQGTQRLG
BKT-P42	PGQWPSSLTLYK
BKT-P23	QIPQMRILHPYG
BKT-P24	QIQKPPRTPPSL
BKT-P115	QLTQTMWKDTTL
BKT-P116	QNLPPERYSEAT

Peptide Name	Sequence of peptide
BKT-P117	QSLSFAGPPAWQ
BKT-P118	QTTMTPLWPSFS
BKT-P119	RCMSEVISFNCP
BKT-P120	RSPYYNKWSSKF
BKT-P39	SAGHIIHEAHRPL
BKT-P40	SAISDHRAHRSH
BKT-P121	SEPTYWRPNMSG
BKT-P32	SFAPDIKYVPVS
BKT-P31	SFWHHHSPRSPL
BKT-P3	SIFAHQPTHKN
BKT-P2	SIPSHSIHSAKA
BKT-P122	SIRTSMNPPNLL
BKT-P123	SLPHYIDNPFRQ
BKT-P29	SLSKANILHLYG
BKT-P124	SLVTADASFTPS
BKT-P125	SMVYGNRLPSAL
BKT-P126	SPSLMARSSPYW
BKT-P127	SPNLPWSKLSAY
BKT-P1	SQTLPYSNAPSP
BKT-P128	SSTQAHPFAPQL
BKT-P129	STPNNSYSLPQAR
BKT-P4	STVVMQPPPRPA
BKT-P34	SVQTRPLFHSHF
BKT-P130	SVSVGGMKPSPRP
BKT-P131	SYIDSMVPSTQT
BKT-P132	SYKTTDSDTSPL
BKT-P133	TAAASNLRAVPP
BKT-P5	TAPLSHPPRPGA
BKT-P134	TGLLPNSSGAGI
BKT-P135	TGPPSRQPAPLH
BKT-P30	TLSNGHRYLELL
BKT-P25	TPSPKLLQVFQA
BKT-P136	TPSTGLGMSPAV
BKT-P137	TPVYSLKLGPWP

Peptide Name	Sequence of peptide
BKT-P47	TRLVPSRYYHHP
BKT-P138	TSPIPQMRTVPP
BKT-P139	TTNSSMTMQLQR
BKT-P140	TTTLPVQPTLRN
BKT-P141	TTTWTITARWPL
BKT-P142	TVAQMPPHWQLT
BKT-P143	TWNSNSTQYGNR
BKT-P144	TWTLPAMHPRPA
BKT-P26	VHTSLLQKHPLP
BKT-P35	VLPNIYMTLSA
BKT-P145	VMDFASPAHVLP
BKT-P146	VNQEYWFFPRRP
BKT-P147	VYSSPLSQLPR
BKT-P148	VPPIS(R)TFLF(L)ST(K)S
BKT-P149	VPPLHPALSRON
BKT-P43	VSPFLSPTPLLF
BKT-P150	VSRLGTPSMHPS
BKT-P151	WPFNHFPWWNVP
BKT-P52	WSAHIVPYSHKP
BKT-P152	WWPNSLNWVPRP
BKT-P53	YATQHNWRLKHE
BKT-P153	YCPMRLCTDC
BKT-P154	YGKGFSFYFHVT
BKT-P155	YPHYSLPGSSTL
BKT-P156	YPSLLKMQPQFS
BKT-P157	YQPRPFVTTSPM
BKT-P158	YSAPLARSNVVM
BKT-P36	YTRLSHNPYTLS
BKT-P41	YTTHVLPFAPSS
BKT-P159	YTWQTIREQYEM

**Table 2:**

Peptide name	Peptide sequence	Bound chemokines (at least)
BKT-P3	SIFAHQTPTHKN	MIG, IL-8, MCP-1
BKT-P2	SIPSHSIHSAKA	MCP-1, Eotaxin, IL-8
BKT-P40	SAISDHRAHRSH	IL-8
BKT-P39	SAGHIHEAHRPL	Eotaxin, SDF-1 $\alpha$ , IL-8
BKT-P48	ACHASLKHRC	MCP-1
BKT-P44	AHSLKSITNHGL	MCP-1
BKT-P51	ESDLTHALHWL	MCP-1
BKT-P49	HSACHASLKHR	MCP-1
BKT-P52	WSAHIVPYSHKP	MCP-1
BKT-P53	YATOHNWRLKHE	MCP-1
BKT-P50	CAHLSPHKC	MIG
BKT-P33	GVHKHFYSRWLG	Eotaxin
BKT-P54	HPTTPFIHMPNF	MIG
BKT-P34	SVQTRPLFHSHF	Eotaxin
BKT-P26	VHTSLLQKHPLP	MCP-1

5

## Amino Acid Composition

H=33

S=22

A=16

10 L=15

I=7

K=10

R=8

T=9

15 P=12

N=3

G=3

W=4

Y=3

20 V=3

E=1

Q=3

O=1

D=2

**Table 3:**

Peptide name	Peptide sequence	Bound chemokines (at least)
BKT-P27	<b>GDFNSGHHTTTR</b>	<b>MCP-1</b>
BKT-P45	<b>HHFHLPLKLRPPV</b>	<b>IL-8, MCP-1, MIG</b>
BKT-P55	<b>HHTWDTRIWQAF</b>	<b>MCP-1</b>
BKT-P46	<b>LDYPIPQTVLHH</b>	<b>MCP-1</b>
BKT-P37	<b>LLADTTTHRPWP</b>	<b>IL-8</b>
BKT-P47	<b>TRLVPSRYYHHP</b>	<b>MCP-1</b>
BKT-P56	<b>CHHNLNSWEC</b>	<b>SDF-1<math>\alpha</math></b>
BKT-P31	<b>SFWHHHSPRSSPL</b>	<b>Eotaxin</b>

## 5 Amino Acid Composition

H=18

P=11

T=9

L=9

10 R=6

W=5

F=4

D=4

G=2

15 N=1

S=7

K=1

V=2

I=2

20 Q=1

Y=2

A=2

**Table 4****Biovalidation Results**

5

Peptide name	Peptide Sequence	Chemokine checked	Level of Antagonistic Effect
<b>BKT-P3</b>	<b>SIFAHQTPTHKN</b>	<b>MIG</b>	<b>+++</b>
		<b>IL-8</b>	<b>+++</b>
<b>BKT-P2</b>	<b>SIPSHSIHSAKA</b>	<b>MIG</b>	<b>++</b>
<b>BKT-P45</b>	<b>HHFHLPLPKLRPPV</b>	<b>IL-8</b>	<b>+++</b>
		<b>MIG</b>	<b>+</b>
<b>BKT-P39</b>	<b>SAGHHIHEAHRPL</b>	<b>Eotaxin</b>	<b>+++</b>
		<b>IL-8</b>	<b>-</b>

Legend: The percentage of antagonistic effect is as follows:

10    + 20%  
 ++ 50%  
 +++ 100%

- No effect

15

20

**References**

Baggiolini, M., and C.A. Dahinden. 1994. *Immunol. Today*, **15**, 127-133.

5 Cocchi, F., Devico, A.L., Garzino-Demo, A., Arya, S.K., Gallo, R.C. and P. Lusso. 1995. *Science*, **270**, 1811-1815.

Ma, Q., Jones, D., Borghesani, P.R., Segal, R.A., Nagasawa, T., Kishimoto, T., Bronson, R.T. and T.A. Springer. 1998. *Proc. Natl. Acad. Sci. USA*, **95**, 9448-9453.

10 Strieter, R.M., Polverini, P.J., Kunkel, S.L., Arenberg, D.A., Burdick, M.D., Kasper, J., Dzuiba, J., Van Damme, J., Walz, A., Marriott, D., et al. 1995. *J. Biol. Chem.*, **270**, 27348-27357.

15 Vaddi, K., and R. C. Newton. 1994. *J. Immunol.*, **153**, 4721-4732.

Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A. 2001. *Nature* **410**, 50-56.

20

## WHAT IS CLAIMED IS:

1. A peptidic chemokine modulator for modulating a biological effect of a chemokine, comprising a molecule composed of the amino acids H, S, A, L, I, K, R, T and P, and featuring at least 2 Histidines spread along said molecule, wherein said molecule features an overall positive charge (family 1).

2. The peptidic modulator of claim 1, wherein said molecule comprises a peptide having an amino acid sequence selected from the group consisting of SIFAHQTPTHKN, SIPSHSIHSAKA, SAISDHRAHRSH, SAGHIHEAHRPL, CHASLKHRC, AHSLKSITNHGL, ESDLTHALHWLG, HSACHASLKHRC, WSAHIVPYSHKP, YATQHNWRLKHE, CAHLSPHKC, GVHKHFYSRWLG, HPTTPIHMPNF, SVQTRPLFHSWF, and VHTSLLQKHPLP.

3. The peptidic modulator of claim 2, wherein said peptide has an amino acid sequence SIFAHQTPTHKN.

4. The peptidic chemokine modulator of any of claims 1-3, for binding to a chemokine selected from the group comprising MIG, MCP-1, IL-8, SDF-1 alpha and Eotaxin.

5. A peptidic chemokine modulator for modulating a biological effect of a chemokine, comprising a molecule composed of the amino acids H, P, T, L, R, W, F, and featuring at least two neighboring histidines, wherein said molecule features an overall positive charge (family 2).

6. The peptidic modulator of claim 5, wherein said molecule comprises a peptide having an amino acid sequence selected from the group consisting of

GDFNSGHHTTTR, HHFHLPKLRPPV, HHTWDTRIWQAF, LDYPIPQTVLHH,  
LLADTTTHRPWP, TRLVPSRYYHHP, CHHNLSWEC and SFWHHHSPRSPL.

7. The peptidic chemokine modulator of claim 6, wherein said peptide has an amino acid sequence LLADTTTHRPWP.

8. A composition for treating a condition involving abnormal cell migration in a subject, the composition comprising a pharmaceutically effective amount of a therapeutic agent for administering to the subject, said therapeutic agent comprising a chemokine modulator as in any of claims 1-7.

9. The composition of claim 8 wherein said condition comprises an inflammatory condition.

10. The composition of claim 8 wherein said condition comprises cancer metastasis.

11. The composition of claim 8, wherein said therapeutic agent is administered by topical administration, such that said composition further comprises a pharmaceutically acceptable carrier for topical administration.

12. The composition of claim 11, wherein said topical administration is to the skin of the subject.

13. The composition of claim 8, wherein said therapeutic agent is administered by inhalation, such that said composition further comprises a pharmaceutically acceptable carrier for inhalation.

14. The composition of claim 8, wherein said therapeutic agent is administered intranasally, such that said composition further comprises a pharmaceutically acceptable carrier for intranasal administration.

15. The composition of claim 8, wherein said therapeutic agent is characterized by an ability to inhibit binding of the chemokine to a chemokine receptor.

16. The composition of claim 8 wherein said therapeutic agent is characterized by an ability to enhance binding of the chemokine to a chemokine receptor.

17. A method for treating a disease modulated through and/or caused by binding of a chemokine to a chemokine receptor in a subject, comprising administering a pharmaceutically effective amount of a therapeutic agent to the subject, said therapeutic agent comprising a peptidic chemokine modulator according to any of claims 1-16.

18. The method of claim 17 wherein said therapeutic agent binds to at least one of the chemokines and wherein said therapeutic agent directly modulates the activity of the chemokine by modulation of binding to the chemokine receptor.

19. The method of claims 17 or 18, wherein said disease is selected from the group consisting of: inflammation (primary or secondary), allergy, a non-optimal immune

response, an autoimmune reaction (including rheumatoid arthritis, systemic lupus erythematosis, multiple sclerosis and others), allograft rejection, diabetes, sepsis, cancer and any type of malignant cell growth, acute and chronic bacterial and viral infections, arthritis, colitis, psoriasis, atherosclerosis, hypertension and reperfusion ischemia.

20. An antibody for binding to a chemokine-binding receptor, comprising:  
an antibody being capable of recognizing at least a portion of a chemokine-binding receptor, wherein said antibody also recognizes a peptide having a sequence according to any of claims 1-7.

21. A vaccine formed with the antibody of claim 20.


22. A method for producing an antibody, comprising:  
inducing formation of antibody against a peptide having a sequence according to any of claims 1-7, wherein said antibody is also capable of recognizing a chemokine-binding receptor.

23. The method of claim 22, wherein said antibody comprises a monoclonal antibody.

24. The method of claim 22, wherein said antibody comprises a polyclonal antibody.

25. The method of any of claims 22-24, wherein said antibody forms a vaccine.

1/5

**Figure 1:**

2/5




Fig. 2

3/5




Fig. 3

4/5

Fig. 4a






Fig. 4b

5/5

Fig. 5



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
4 September 2003 (04.09.2003)

PCT

(10) International Publication Number  
**WO 03/072599 A3**

(51) International Patent Classification<sup>7</sup>: C07K 7/08, (7/64, A61K 38/10, C07K 16/44, 16/28)

(21) International Application Number: PCT/IL03/00155

(22) International Filing Date: 27 February 2003 (27.02.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/359,995 28 February 2002 (28.02.2002) US

(71) Applicant (for all designated States except US):  
**BIOKINE THERAPEUTICS LTD.** [IL/IL]; Building 13a, Kiryat Weizmann, 70400 Nes Ziona (IL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **PELED, Amnon** [IL/IL]; Balfour Street 33b, 65211 Tel Aviv (IL). **EIZEN-BERG, Orly** [IL/IL]; Gordon Street 43A, 76287 Rehovot (IL). **VAIZEL-OHAYON, Dalit** [IL/IL]; HaOfek Street 2, 47027 Nes Ziona (IL).

(74) Agent: **G.E. EHRLICH (1995) LTD.**; Bezalel Street 28, 52521 Ramat Gan (IL).

(81) Designated States (national): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:  
18 December 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/072599 A3

(54) Title: NOVEL CHEMOKINE BINDING PEPTIDES CAPABLE OF MODULATING THE BIOLOGICAL ACTIVITY OF CHEMOKINES

(57) Abstract: Novel peptidic or peptidomimetic agents or small molecules for modulating the biological effect of a chemokine. According to the present invention, the therapeutic agents preferably are endowed with the capacity to bind to certain chemokines in order to modulate the biological interaction between the target ligand, chemokine, and the respective target receptor, chemokine receptor. These peptides may be described as agonist ligands or antagonists. Next, preferably certain peptides share consensus sequences which characterize the families or categories of these modulator peptides.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/IL 03/00155

**A. CLASSIFICATION OF SUBJECT MATTER**  
 IPC 7 C07K7/08 C07K7/64 A61K38/10 C07K16/44 C07K16/28

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**Minimum documentation searched (classification system followed by classification symbols)  
 IPC 7 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, EMBL, MEDLINE, EMBASE, BIOSIS, CHEM ABS Data, WPI Data, PAJ

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DATABASE EMBL 'Online! 16 AA, 4 March 2003 (2003-03-04) "G PROTEIN-COUPLED RECEPTOR (GPCR) ANTIGENIC PEPTIDE SEQ ID N°944" retrieved from EBI Database accession no. abp82271 XP002253478 the whole document	
P, A	-& WO 02 61087 A (LIFESPAN BIOSCIENCES INC) 8 August 2002 (2002-08-08) ---	
A	PROUDFOOT A.E.I. ET AL.: "The strategy of blocking the chemokine system to combat disease." IMMUNOLOGICAL REVIEWS, vol. 177, 2000, pages 247-256, XP002253477 page 253 -page 255 --- -/-	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

9 September 2003

Date of mailing of the international search report

24/09/2003

## Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Bladier, C

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/IL 03/00155

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	HAYASHI S ET AL: "SYNTHETIC HEXA- AND HEPTAPEPTIDES THAT INHIBIT IL-8 FROM BINDING TO AND ACTIVATING HUMAN BLOOD NEUTROPHILS" JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 154, 1995, pages 814-824, XP002913718 ISSN: 0022-1767 -----	

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

Continuation of Box I.2

Claims Nos.: 1-25 (partially)

Present claims 1 and 5 are directed to a compound characterized partly by a desirable property (the ability to modulate the biological effect of a chemokine). In addition, the subject-matter of these claims is defined using unclear wordings ('comprising') and unclear technical features (it can not be understood of how many of the amino acids H, S, A, L, I, K, R, T and P the molecule is composed). As a consequence claims 1 and 5 (and claims depending thereon) relate to an extremely large number of possible compounds.

Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed.

In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds presented in tables 2 and 3.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/IL 03/00155

### Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 17-19 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.: 1-25 (partially)  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of Invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/IL 03/00155

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0261087	A 08-08-2002	WO 02061087 A2	08-08-2002